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ABSTRACT 
BACKGROUND:  Adverse drug reactions (ADRs) are a leading cause of morbidity 
and mortality. In the United States, ADR-related morbidity and mortality costs have 
been estimated at US $30 billion to US $130 billion annually. 
OBJECT IVES:  The aim of this study was to evaluate the incidence of ADRs in 
Taiwan, to identify the drug classes that are most commonly related to ADRs, and to 
determine the direct medical costs to hospitals associated with prolonged hospitaliza- 
tions due to ADRs. 
METHODS:  In this prospective, descriptive, observational study, patients who 
experienced ADRs during their hospitalization at a Taiwan teaching hospital or who 
were admitted ue to an ADR from January 1, 2002, through December 31, 2004, 
were included in the study. The patients were identified actively by clinical pharma- 
cists and passively by physicians and nurses who reported ADRs. The World Health 
Organization (WHO) definition of ADR severity was adopted, and degrees of proba- 
bility for each ADR were determined using the Naranjo algorithm. The direct medi- 
cal costs incurred to the hospital in the treatment of ADRs that prolonged hospitaliza- 
tion were calculated (ie, costs of emergency department fED] visits, intensive care 
unit visits, extra days of hospitalization, monitoring and laboratory studies, pharma- 
cist dispensing fees, physician fees, room charges, ED charges). 
RESULTS:  During the study period, 43 of the 142,295 hospitalized patients 
(0.03 %) were admitted because of an ADR. A total of 564 (0.40%) of the hospitalized 
patients were verified to have ADRs. Three hundred eighteen of the patients (56.4%) 
with ADRs were male and the overall mean (SD) age was 66 (2) years. The most com- 
mon drug classes associated with the ADRs were antibiotics (219 patients {38.8%]), 
analgesics (62 [11.0%]), and cardiovascular gents (56 [9.9%]). The systems most 
commonly involved in ADRs were cutaneous (296 patients [52.5%]), hematologic 
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(61 [10.8%]), and cardiovascular (54 [9.6%]). The causes of the ADRs were anaphy- 
lactic (464 patients [82.3 %]), drug overdose (78 [ 13.8 %]), and drug~trug interactions 
(22 [3.9%]). Of the ADRs, 474 (84.0%) were idiosyncratic type B reactions (predict- 
able). ADR-related costs, estimated at US $3489/ADR, were mostly due to prolonged 
length of stay. Based on the WHO definition, of the 564 ADRs, 330 (58.5%) and 
40 (7.1%) were classified as moderate and severe, respectively. Two patients died of 
ADRs associated with allopurinol. 
CONCLUS|ON:  In this hospital, 0.40% of patients were identified as having 
ADRs that were associated with high direct costs, mostly due to extended hospitaliza- 
tions. (Cur*" Thef Res Cliv Exp. 2008;69:118 129) g) 2008 Excerpta Medica Inc. 
KEY WORDS:  direct medical cost, adverse drug reactions. 
INTRODUCTION 
Adverse drug reactions (ADRs) are a leading cause of morbidity and mortality. 1,2 
ADRs have been estimated to account for up to 106,000 deaths annually in the 
United States. 1,2 Additionally, ADRs are the cause of hospital admission in 3% to 6% 
of patients of all ages 3,4 and 3% to 24% of elderly patients. 5 The incidence of fatal ADRs 
has been found to be 0.15% to 0.41% in Western countries. 1,4 In the United States, 
ADR-related morbidity and mortality costs have been estimated at US $30 billion to 
US $130 billion annually. 6,7 
ADRs are generally defined as any undesirable ffbct of a drug beyond its antici- 
pated therapeutic effect that occurs during clinical use. s Although many ADRs are 
mild and disappear when the causative drug is discontinued or the dose is reduced, 
some are serious and permanent. Therefore, ADRs might increase not only morbidity 
and mortality but also health care costs. 
A nationwide ADR reporting system was established in Taiwan in 1986, but no 
statistical analysis data have been previously reported. Although the clinical pharmacy 
departments in all hospitals in Taiwan contribute to the ADR reporting and monitor- 
ing programs, the reporting rate of physicians remains low (0.003%), 9 compared with 
rates reported in the United States (0.19%) 9and Australia (1.09%). 1° 
The aim of this study was to analyze the characteristics of all ADRs reported in our 
hospital, including the incidence of ADRs, the classes of drugs that were most com- 
monly associated with ADRs, the relation of the drugs with the ADRs, the type and 
severity of each ADR, and the direct medical costs to the hospital. 
PAT IENTS AND METHODS 
This prospective, descriptive, observational study was conducted from January 1, 2002, 
to December 31, 2004, at the 1083-bed Chi Mei Medical Center, a tertiary teaching 
hospital in ~lhinan, Taiwan. Institutional review- board approval was not required for 
this study. Patient confidentiality was maintained throughout the course of the study. 
The medications associated with the ADRs were classified in accordance with the 
hospital formulary. ADRs were defined according to the World Health Organization as 
"any response to a drug which is noxious and unintended, and which occurs at doses 
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normally used in humans for prophylaxis, diagnosis, or therapy of disease, or for the 
modification of physiological function. ''8 
Patients who experienced ADRs during their hospital stay or were admitted ue to 
ADRs were identified and included in the study. The ADR reporting system involves 
both active and passive methods routinely conducted in Taiwanese hospitals. Active 
methods included the identification, by clinical pharmacists, of any suspected ADRs 
through ward rounds and prescribed rugs (eg, naloxone for the reversal of narcotic 
depression). The passive method was spontaneous reports from pharmacists, physi- 
cians, and nurses (hereafter called reporters) of suspected ADRs using a computerized 
automatic reporting system or paper ADR reporting forms. All cases were reviewed 
by clinical pharmacists to exclude ADRs reported in duplicate through the 2 re- 
porting methods. Any suspected ADRs were reported by entering the name of 
reporter and units, patients' brief data, the name of suspected rugs, and suspected 
ADR. Patients who developed an ADR during hospitalization and patients whose 
admission resulted from an ADR were assessed by a clinical pharmacist and their 
responsible physicians on receipt of the ADR reporting fbrrn using the Naranjo 
algorithm. 11 ADRs were classified as def~elite (score 9 or 10), probable (5 8), possible 
(1~1), or doubtful (0) in regard to their relation with a particular drug. ADR severity 
was assessed according to the criteria developed by ttartwig et al. 12 This scale catego- 
rized each ADR as mild, moderate, or severe. 
A probability category for each ADR was assigned according to the Naranjo 
scale. M The cause of an ADR was considered type A (augmented pharmacologic 
ef}bcts) or B (idiosyncratic). 13 ADRs were defined as miM if they were self21imiting, 
resolved over time without treatment, and did not affect he length of hospitalization. 
Moderate ADRs were those that required therapeutic ntervention, prolonged hospital- 
ization by 1 day, or caused the patient to be admitted to the hospital. Severe ADRs 
were those that were life threatening, carcinogenic, or permanently disabling, pro- 
longed hospitalization by >1 day, or caused death, s Patient ADR outcomes were 
reported as follows: fully recovered; not fully recovered; death; or unknown. 
To measure the impact of ADRs on direct medical costs and length of stay, data 
were collected from the hospital's claims database. The extra days of stay associated 
with ADRs were marked as the difference between the beginning and end of the 
ADR. The beginning of the ADR was the date of hospital admission due to the ADR 
or, if the event occurred uring hospitalization, the date of the clinical or biological 
diagnosis of the ADR. The end of the ADR was the date of hospital discharge or the 
date of normalization of the effect, including the date of laboratory examination with 
normal results or the disappearance of clinical symptoms reported by physicians dur- 
ing hospitalization. The direct medical cost incurred in treating the ADRs was calcu- 
lated for each medical service, physician fee, and laboratory test (by day rate) based on 
the hospital's claims data system. For ADRs requiring discontinuation of the sus- 
pected drugs, the cost for treatment was considered as zero. When ADRs required 
extra medications, treatments, or laboratory tests, the costs of these (eg, all drug costs, 
physician fees, pharmacist dispensing fees, laboratory test fees, room charges) were 
included in calculating the cost incurred by the patient. 
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STAT IST ICAL  ANALYS IS  
Descriptive analysis was conducted for quantitative variables. Mean values and the 
X 2 test were used to compare the distributions of categorical variables. Data are pre- 
sented as mean (SD). Categorical variables are expressed as a percentage of the total 
number of ADRs. P < 0.05 was considered statistically significant. 
RESULTS 
During the study period, 43 of the 142,295 hospitalized patients (0.03%) were ad- 
mitted because of an ADR. A total of 564 (0.40%) of the hospitalized patients were 
verified to have ADRs (318 males [56.4%]; mean [SD] age, 66 [2] years). The age 
distribution of patients with ADRs and of the general popuhtion of hospitalized 
patients is shown in Table I. 
The correlation of ADR rate with gender was not statistically significant (Table II). 
ADR rates increased with age from 1.34/1000 patients for the age range of 0 to 10 years 
to 6.95/1000 patients for the age range of 71 to 100 years (P < 0.001) (Table III). 
All 564 ADRs were detected by either the active or the passive ADR reporting 
system. Clinical pharmacists reported 257 of the ADRs (45.6%), nurses reported 
204 (36.2%), and physicians reported 85 (15.1%). The remaining 18 (3.2%) were 
reported by the patient or a family member. 
The therapeutic classes of the drugs associated with the ADRs are shown in Table IV. 
Antibiotics were the most frequent cause of ADRs, with 219 patients (38.8%) ex- 
periencing an ADR associated with this drug class. 
The most common clinical manifestations of the ADRs are listed in Table V. The most 
common ADRs with clinical manifestations were cutaneous (296 patients [52.5%]) and 
hematologic (61 [10.8%]) (Table VI). Among the most frequently observed ADRs 
were rash (172 patients [30.5%]) and local rash at the injection site (37 [6.6%]) 
(Table V), with most cases being classified as mild, resolved with the highest recovery 
rates (75%), and caused by the first-generation cephalosporin cephazolin. The most 
severe dermatologic ADR was Stevens Johnson syndrome; 2 patients experiencing 
this reaction died. Hematologic ADRs were the second most frequently rated as se- 
vere in intensity (11/61 [18%]); thrombocytopenia w s the most frequently occurring 
(6.9%). Regarding the probability of ADRs, 413 of ADRs (73.2%) reported were 
identified as probable, indicating that they were more likely to be associated with the 
suspected rug, according to the Naranjo probability scale. 11 Two reported ADRs 
(0.4%) were considered oubtful. The majority of ADRs (474 [84.0%]) reported were 
considered predictable, type B reactions (Table VII). 
Gastrointestinal ADRs had the lowest recovery rates (1/28 [3.6%]), because most 
of the patients experienced vomiting and diarrhea nd were not fully recovered before 
discharge; however, none of these reactions resulted in death (Table VIII). 
Hospitalizations or extensions of hospitalization due to ADRs accounted for a total 
of 530 additional days of hospitalization (Table IX). The total cost of treating ADR- 
related illness collected from the hospital claims data was estimated to be US 
$150,027.14 (Table X). The cost of treating each ADR that was associated with 
extended hospitalization ( 42) was estimated to be US $3489.00. 
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Table II. Correlation of adverse drug reaction (ADR)-related hospitalizations with sex in 
Taiwanese patients,* 
Sex ADR-Reiated Not ADR-Related Total 
Male 
No. 318 76,569 76,887 
Rate (per 1000 patients) 4.14 995.86 
Female 
No. 246 
Rate (per 1000 patients) 3.76 
Total 564 
65,162 65,408 
996.24 
141,731 142,295 
*No significant between-gender differences were observed. 
Table III, Correlation of adverse drug reaction (ADR)-related hospitalizations by age 
group in Taiwanese patients, 
Age Group, y 
Variable 0-10 11-20 21-40 41-70 71-100 Total 
No. of patients 
(ADR-related hospitalization) 20 26 78 224 216 564 
Rate (per 1000 patients) 1.34 4.70 2.72 3.61 6.95* 3.96 
No. of patients 
(non-ADR-related 
hospitalization) 14,915 5506 28,600 61,830 30,880 141,731 
Rate (per 1000 patients) 998.7 995.3 997.3 996.4 993.1 996.0 
Total no. of patients 14,935 5532 28,678 62,054 31,096 142,295 
*P < 0.001 versus all other age groups. 
DISCUSSION 
In this study, we found that 0.03% (43/142295) of hospitalized patients were admit- 
ted because of an ADR. A total of 564 (0.40%) hospitalized patients experienced an 
ADR during their hospital stay. These figures appear much lower than data from 
published studies f~om other countries (2.9% 35.0%). 3'4'14 
Physicians in Taiwan may underreport ADRs, even though most medical centers 
have a well-established ADR reporting system connected to the central reporting 
center. Clinical pharmacists also promote ADR reporting through presentations about 
ADRs at physicians' morning meetings and through promotional materials and a 
newsletter. Additionally, ADR reporting is a basic requirement ofhospital accredita- 
tion in Taiwan. However, the ADR reporting rate remains low (0.003%), possibly due 
to physicians' concerns about liability. This phenomenon may also occur in Western 
countries. 15One study reported that their ADR-reporting method supported the 
observation oftraditional ADRs reporting are markedly underreported in hospitalized 
patients because the reporting system is physician dependent.l~ 
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Table IV. Therapeutic classes of drugs associated with adverse 
drug reactions in Taiwanese patients (N = 564), 
Drug Class Patients, No. (%) 
Antibiotic 219 (38.8) 
Analgesic 62 (11.0) 
Cardiovascular 56 (9.9) 
NSAID 32 (5.7) 
Anticonvulsant 29 (5.1) 
Anticoagulant 27 (4.8) 
Gastrointestinal 17 (3.0) 
AntEuberculosis 14 (2.5) 
Respiratory system 14 (2.5) 
Antidiabetic 13 (2.3) 
Antigout 13 (2.3) 
Chemotherapy 13 (2.3) 
Central nervous system 9 (1.6) 
Metabolic 6 (1.1) 
Antipyretic 4 (0.7) 
Muscle relaxant 4 (0.7) 
Narcotic 4 (0.7) 
Hormone 3 (0.5) 
Steroid 3 (0.5) 
Antineoplastic 2 (0.4) 
Antiplatelet 1 (0.2) 
Dermatology 1 (0.2) 
Other 18 (3.2) 
Table V, Clinical manifestations of the adverse drug reactions 
(ADRs) in Taiwanese patients (N = 564),  
ADR Patients, No. (%)* 
Rash 172 (30.5) 
Thrombocytopenia 39 (6.9) 
Local rash at injection site 37 (6.6) 
Increased GOT/GPT 26 (4.6) 
Bleeding 25 (4.4) 
Bradycardia 23 (4.1) 
Neutropenia 20 (3.6) 
Diarrhea 14 (2.5) 
Tremors 10 (1.8) 
Other 198 (35.1) 
GOT = glutamate oxaloacetate transaminase; GPT = glutamic-pyruvic 
transaminase. 
*Totals may not sum to 100% due to rounding. 
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Table VI. Frequency of the adverse drug reactions by organ sys- 
tem and cause in Taiwanese patients (N = 564). 
Variable Patients, No. (%)* 
Organ system 
Cutaneous 296 (52.5) 
Hematologic 61 (10.8) 
Cardiovascular 54 (9.6) 
Hepatic 33 (5.9) 
Gastrointestinal 28 (5.0) 
Other 92 (16.3) 
Cause 
Anaphylactic 464 (82.3) 
Drug overdose, duration too long 78 (13.8) 
Drug-drug interaction 22 (3.9) 
*Totals may not sum to 100% due to rounding. 
Table VII. Frequency of adverse drug reactions in faiwanese 
patients by probability, type, and severity as defined 
by the World Health organization, s 
Variable Reactions, No. (%) 
Probability 11 
Definite 23 (4.1) 
Probable 413 (73.2) 
Possible 126 (22.3) 
Doubtful 2 (0.4) 
Type 
Type A 90 (16,0) 
Type B 474 (84,0) 
Severity 
Mild 194 (34.4) 
Moderate 330 (58.5) 
Severe 40 (7.1) 
We found that the proportion of ADR-related hospitalizations increased with age 
from 0.22% in patients aged <21 years to 0.69% in patients aged >71 years, which 
confirms a previous study that found that older patients have significantly more 
ADR-related problems. 17 This observation suggests that increasing age is a risk factor 
for the occurrence of ADRs, which might be related to the increased number of drugs 
elderly patients receive, the use of drugs that are inappropriate for elderly patients, 
and the number of previous illnesses. 17,18 
ADR rates did not vary significantly by gender in our study, which differed from 
the findings of previous tudies. 19,20 They found that female sex was associated with 
a greater number of ADR-related problems. 
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Table IX. Costs associated with adverse drug reactions (ADRs) by drug class in 
Taiwanese patients. All costs are  in 2006 US $. 
Extra Monitoring 
ED ICU Days of and 
Drug/ ADRs, Visits, Visits, Hospitalization, Drug Laboratory 
Drug Class n n n n Costs Costs 
Antibiotics 6 6 0 118 109,294.60 903,796.00 
Sedative/hypnotic 0 0 0 0 0 0 
Antiepileptic 12 11 3 159 93,649.42 422,229.00 
Antipsychotics 0 0 0 0 0 0 
Antidepressant 0 0 0 0 0 0 
Cardiovascular 8 6 0 78 20,495.89 98,837.00 
Endocrine drugs 4 4 2 80 140,799.30 1,088,692.00 
Immunosuppressant 0 0 0 0 0 0 
Gastrointestinal 1 0 0 0 2064.20 9140.00 
Miscellaneous 12 10 3 95 352,523.60 531,972.00 
Total 43 37 8 530 22,323.80 94,865.40 
ED = emergency depar tment ;  ICU = intensive care unit. 
Table X. Total cost associated with adverse drug reactions (ADRs) in Taiwanese 
patients. All costs are in 2006 US $. 
Total 
Pharmacist Cost 
Dispensing Physician Room ED (US $1 = 
Fee Fee Charges Charges NT $32.2) 
Total Cost 1172.42 5158.88 25,932.11 574.53 150,027.14 
Average cost/ADR 3489.00 
ED = emergency depar tment ;  NT $ = Taiwanese new dol lar  
As reported in previous tudies, 21 the most connnonly affected organ system associ- 
ated with ADRs in our study was the skin (52.5 %). Two patients died of allopurinol- 
related Stevens-Johnson syndrome, which is the second most connnon drug associated 
with fatal ADRs. 22 
Consistent with published studies, 2°,21 the ADRs in our study were most fre- 
quently associated with antibiotics (38.8%), analgesics (11.0%), and cardiovascular 
drugs (9.9%). The most common ADR was rash related to treatment with 
cephazolin. 
A probability category for each ADR was assigned based on the Naranjo scale. 11 
The results of the assessment were submitted to the Pharmaceutical nd Therapeutic 
(P&T) Committee of our hospital for further evaluation. The results of the P&T evalu- 
ation were then reported to the National Adverse Drug Reporting Center of Taiwan. 
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Our hospital incurred a mean of US $283 for 1 additional ength of stay associ- 
ated with an ADR. One study 23 identified longer hospital stays as directly contributing 
to increased ADR costs. Two studies 2,23 concluded that the increase in the cost of hos- 
pitalization for an ADR was US $3800 and US $3200, respectively. Another study 24 
found that the mean additional cost of hospitalization for an ADR was US $1400. 
In our study, the mean cost of an ADR associated with extended hospitalization was 
US $3489. The higher costs determined by some previous tudies might be due to the 
severity of the ADRs, as patients with cardiovascular nd hemorrhagic ADRs related to 
cardiovascular o anticoagulant drugs may be transferred to the intensive care unit. 25 
However, the severe ADRs in our study were hematologic and cutaneous (ie, Stevens- 
Johnson syndrome, neutropenia, thrombocytopenia). 
A limitation of this study was that the rate of ADR-related hospitalization was 
probably an underestimate b cause of underreporting or misclassification, because all 
ADRs possibly were not identified. 2(5 The actual number of ADRs in our patients 
might also have been higher than the number of ADRs detected uring hospitali- 
zation because of the relatively short length of stay in our hospital (mean, 7 days). 
Therefore, some ADRs triggered by the drugs used during hospitalization may have 
occurred in the outpatient department. 
CONCLUSION 
In this hospital, 0.40% of patients were identified as having ADRs that were associ- 
ated with high direct costs, mostly due to extended hospitalizations. 
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